Articles

Dronedarone, a new Class III multi-channel blocking anti-arrhythmic drug currently in Phase III development by Sanofi-Aventis for the prevention of atrial fibrillation (AF) and atrial flutter (AFL) may help fill the unmet need for a safe pharmacologic treatment that effectively controls atrial fibrillation, cardiologists said this month. Sanofi-Aventis presented new data on dronedarone at the American Heart Association’s (AHA) annual scientific sessions held in Dallas.
Dronedarone, a new Class III multi-channel blocking anti-arrhythmic drug currently in Phase III development by Sanofi-Aventis for the prevention of atrial fibrillation (AF) and atrial flutter (AFL) may help fill the unmet need for a safe pharmacologic treatment that effectively controls atrial fibrillation, cardiologists sa…

Patients who could benefit from injectable therapies are a lot less needle-phobic than doctors assume, according to research conducted by pharmacist and behavioural scientist Professor Robert Horne. The “Open Mind” study presented at the 10th European AIDS Conference/EACS in Dublin showed over three quarters of patients would be willing to accept self-administered subcutaneous injectable therapy if offered.
Patients who could benefit from injectable therapies are a lot less needle-phobic than doctors assume, according to research conducted by pharmacist and behavioural scientist Professor Robert Horne.  The “Open Mind” study presented at the 10th European AIDS Conference/EACS in Dublin showed over three quarters of patients would be willing to accept self-administered subcutane…

In the first article on acquisitions and joint ventures, we saw how despite the odds on an acquisition adding value for shareholders being only one in three, companies like Johnson & Johnson, Pfizer, Sosei and Amphion Innovations are still racing ahead. Now we take a glimpse at the similarly challenging world of joint ventures – and then look at how companies can increase the odds with a little forward planning.
Improving the odds for acquisitions and joint ventures Part II In the first article on acquisitions and joint ventures, we saw how despite the odds on an acquisition adding value for shareholders being only one in three, companies like Johnson & Johnson, Pfizer, Sosei and  Amphion Innovations are still racing ahead. Now we take a glimpse at the similarly challenging…

Caution: Your CV is your personal data. My advice as a recruiter, with many years experience in the clinical research industry, would be to take care where you send your CV and make sure your data is treated with the respect it deserves! The important thing is to be selective.
Recruitment websites can be confusing, strange places to the inexperienced.  If you are not sure, select an established agency with a name you recognise.  Follow the link to their website and find a contact name. Email or phone them to ask for advice. If the website doesn’t give you information about their recruiters, maybe it is best to give them a miss. Using the internet is supposed to be speedy and convenient.   However, a common complaint we hear is that sending off a CV to some recruitm…

e-Detailing is one of the pharmaceutical industry's biggest buzz terms of the moment, but it is one that, for the moment at least, seems unlikely to go away. This informative paper will help you under
By Dr. Andre Bates, Originally Published in International Journal of Medical Marketing, May 2002, Vol 2 Number 3 Abstract: eDetailing is currently under consideration by many pharmaceutical companies as a way to maximise sales force time, cut costs and increase physician prescribing. eDetailing is not a single entity but can take many different forms: from remote live discussion with a sales rep to a purely scripted interaction with a web site or an Interactive Voice Response phone line. Most eDetailing models have been tried in the US and only some models such as some forms of Scripted eDeta…

Acquisitions, joint ventures and strategic alliances have become the norm across industry and the life science and technology sectors are no exception.
Part I   Acquisitions, joint ventures and strategic alliances have become the norm across industry and the life science and technology sectors are no exception. A recent Deloitte Life Sciences report highlighted that firms can no longer rely on internal resources for growth, but need to seek out acquisitions, mergers, alliances and exploratory relationships. It added that 92% of life science executives expect further consolidation, mainly through acquisition. Yet with the odds on an acquisition adding value for shareholders standing at just one in three, CEOs need to improve their chances of success. A brief look at the figures is rea…

Due to increasing interest and requests regrding the subject Pharmiweb have created a new Avian Flu resource page.
Pharmiweb are (within reason) pleased to announce the integration of an Avian Flu resource centre onto our main site. Due to the seriousness of the current situation and the global spread of the virus, we have had multiple requests for information and further reading regarding the subject. Avid readers will have access to all the latest information and news regarding the migration of the virus and its effects on the consumer, the Pharma industry and how governments are planning to tackle this potential crisis. In addition to frequently updated news you will find related features, press releases, and useful resource links. Take a browse and let us know what you think! http:…

Due to demand, we at PharmiWeb have added a new Executive Jobs Listing to our comprehensive careers section. All these jobs include packages of over £100K (GBP) per year.
We are pleased to announce that, due to demand, we have added a new section to the site. Executives in the Pharmaceutical industry can now find the best selection of jobs with packages of £100K+ (GBP) per year. These executive pharma jobs are automatically taken from our extensive database of over 4800 live jobs, provided by our partners in Agencies and PharmaCos across the industry. This means that the listing will be constantly updated with new jobs as soon as they are posted. Visit our new Executive Jobs page here.

Australia, "The Lucky Country", is renowned for its expanse of white sandy beaches, world heritage landscape, vineyards producing first class wines, high standard of living, excellent health and education systems, temperate climate and generally a lifestyle envied by many around the world. It is no wonder that a steady stream of clinical research professionals from all over the world are looking for a scene change here.
In the last 25 years, Australia has become the number one destination for permanent migration. The country's non-discriminatory immigration policy guarantees that any person can apply to migrate to Australia from any country in the world, no matter what their sex, colour, ethnic origin or religion, provided they meet objective visa criteria. These criteria generally relate…

For those new to the industry, a quick round up of the common abbreviations and what they stand for might be useful....
ABPI Association of British Pharmaceutical Industry ADME Absorption, Distribution, Metabolism and Excretion ADR Adverse Drug Reaction AE Adverse Event CPMP Committee for Proprietary Medicinal Products CRF Case Report Form CSM Committee on Safety of Medicines CTC Clinical Trial Certificate CTX Clinical Trial Certificate of Exemption DBDD Double Blind Double Dummy EMEA European Medicines Evaluation Agency FDA Food and Drug Administration GCP Good Clinical Practice GMP Good Manufacturing Practice IDB Investigators’ Drug Brochure IEC Independent Research Ethics Committee MAA Marketing Authorisation Approval MHRA Medicines and Healthcare Produ…

Complete our user survey and you could win a £25 Amazon voucher!
Yes, take part in the PharmiWeb.com Autumn survey and your name will go into the hat for our monthly prize draw. Simply answer a few question and give us some of your valuable feedback, and each month we'll pull a name out of the hat for a £25 Amazon Voucher. It will only take a couple of minutes to complete, so what are you waiting for... Complete the survey

The prevalence of diabetes, in particular type 2 diabetes, is increasing worldwide. Type 2 diabetes increases with age, but recently has been affecting much younger individuals. In the UK, diabetes prevalence has doubled over the last 12-15 years, and is set to double again over a similar timeframe. The prevalence of diabetes in the UK is now, on average, 3.3%, though many patients are undiagnosed.
The prevalence of diabetes, in particular type 2 diabetes, is increasing worldwide. Type 2 diabetes increases with age, but recently has been affecting much younger individuals. In the UK, diabetes prevalence has doubled over the last 12–15 years, and is set to double again over a similar timeframe. The prevalence of diabetes in the UK is now, on average, 3.3%, though many patients are undiagnose…

Bristol-Myers Squibb was named today as one of the 10 Best Companies for Working Mothers by Working Mother magazine. This is the eighth consecutive year that the company has been listed in the ranking of the 100 Best Companies, and the fifth year in a row Bristol-Myers Squibb has been named a Top 10 company.
Bristol-Myers Squibb Named  one Of The 10 Best Companies For Working Mothers Celebrates Fifth Consecutive Year on "Top 10" List NEW YORK, NEW YORK (September 12, 2005) - Bristol-Myers Squibb was named today as one of the 10 Best Companies for Working Mothers by Working Mother magazine. This is the eighth consecutive year that the company has been listed in the ranking of the 100 Best Companies, and the fifth year in a row Bristol-Myers Squibb has been named a Top 10 company. Bel…

The European and US neuropathic pain markets are currently worth $2.5 billion combined. While most drugs currently used are not primarily indicated for neuropathic pain, the blockbuster status of Neurontin in this indication has focused the attention of several pharmaceutical giants on this potentially lucrative market. As such, Datamonitor expects the market to be worth over $4 billion by 2007.
Neuropathic pain is defined as pain associated with a functional abnormality of the nervous system. Clinical features can include an abnormal, unpleasant sensation (dysesthesia) that frequently has a burning or electrical sensation with occasional brief shooting or stabbing pain. Although the onset of most neuropathic pain is within days after the precipitating injury, there is no absolute temporal…

On Wednesday 22nd June, PharmiWeb Solutions and Microsoft brought together a senior group of sales and marketing professionals, to discuss how software and e-business based solutions can deliver competitive advantage for the pharmaceutical organisation.
On Wednesday 22nd June, PharmiWeb Solutions and Microsoft brought together a senior group of sales and marketing professionals, to discuss how software and e-business based solutions can deliver competitive advantage for the pharmaceutical organisation.   “In planning for this event, we were keen to avoid the usual traps of either speaking techno-babble, or failing to focus on business issues, and so I hope with our range of speakers that we were able to draw attention to how the practical application of technology-based solutions can…

Pharma Sales World 2005 will provide delegates with a unique opportunity to gain critical business information about how Europe’s leading pharma companies are addressing the challenge of improving sales force effectiveness. The conference will highlight the issues of accessibility, emerging customer bases, market changes in the next decade, sales force size and structure, targeting and segmentation, the new breed of representative, data acquisition, training and development, customer relationshi
Never before has the industry been positioned for such dramatic change as what the pharmaceutical sector is currently facing, creating more uncertainty in an already challenging market. At Pharma Sales World 2005 we have an exceptional programme that will provide creative solutions for the toughe…

Fractures resulting from osteoporosis are widely recognised as a major cause of morbidity and mortality in the elderly population. It has been estimated that approximately 310,000 osteoporotic fractures occur annually in the UK, with a consequent cost to the health service of £1.7 billion.
Fractures resulting from osteoporosis are widely recognised as a major cause of morbidity and mortality in the elderly population. It has been estimated that approximately 310,000 osteoporotic fractures occur annually in the UK, with a consequent cost to the health service of £1.7 billion. Over the past two decades major advances have been made in the management of this disease and a number of pharmacological agents have been approved for the reduction of fracture risk in postmenopausal women with osteopo…

On Friday 16th September, before a glittering audience of local business Champions, Exco was awarded the highly acclaimed prize of Small Business of the Year 2005.
  The Small Business of the Year Award was presented in recognition of Exco’s successful implementation of a strategic business development plan, leading to growth within an increasingly competitive environment. The judges were unanimous in their statement confirming that Exco is ‘Truly Entrepreneurial, this Company is committed to achieving Best Practice in every aspect of its Business’.  The organization has benefited from a strategic approach where objectives are outlined and all staff are encouraged to participate in driving the business forward. This has lead to continued success across every division, a steady gro…

The pharmaceutical industry’s new molecular entity (NME) submissions to the U.S. FDA and new active substance (NAS) submissions to the European Medicines Evaluation Agency (EMEA) rose to five-year highs in 2004, according to PAREXEL’s Pharmaceutical R&D Statistical Sourcebook 2005/2006.
The pharmaceutical industry's new molecular entity (NME) submissions to the U.S. FDA and new active substance (NAS) submissions to the European Medicines Evaluation Agency (EMEA) rose to five-year highs in 2004, according to PAREXEL's Pharmaceutical R&D Statistical Sourcebook 2005/2006. The FDA received 31 NME submissions in 2004, while the EMEA received 45 NAS submissions under its centralized registration procedure, through which a drug can gain access to all 25 countries in the European Union via a…

Any nurse can start a business, including two-year graduates and diploma nurses. No advance degrees are necessary unless your business includes diagnosing and treating medical problems. State nurse practice acts do no prohibit a nurse from starting up their own business as an Independent Nurse Contractor.
Career Options For The Ambitious Nurse Entrepreneur Nurses are taking control of their careers by exploring options other than the traditional roles of yesteryear. Independent RN Contractors are storming the healthcare field. There was a time when nurses were hesitant about cutting the ties from the employer not true today. More and more nurses are now enjoying the many benefits of self-employment. Nurse Contractors are now a large part of the nursing industry thanks to the ambitious n…